Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Status
- RECRUITING
- Phase
- N/A
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
- Status
- COMPLETED
- Phase
- PHASE2
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
- Status
- COMPLETED
- Phase
- PHASE2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
- Status
- COMPLETED
- Phase
- PHASE1
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
- Status
- UNKNOWN
- Phase
- N/A
Corifollitropin Alfa and Embryo Morphokinetics
- Status
- COMPLETED
- Phase
- N/A
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
- Status
- TERMINATED
- Phase
- PHASE1
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
- Status
- COMPLETED
- Phase
- PHASE1
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
- Status
- COMPLETED
- Phase
- PHASE3
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE3